Mereo BioPharma

Mereo BioPharma is a biopharmaceutical company focused on developing innovative therapies for rare diseases. The company has two rare disease candidate products: setrusumab for the treatment of osteogenesis imperfecta (OI), and alvelestat, primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).